SCHEMBL3637488

SCHEMBL3637488

CC(C)(C)c1n[nH]cc1CNc1cccc(-c2cccs2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.42
HDAC1 Q13547 3/20 0.35
HDAC2 Q92769 3/20 0.35
HTR1A P08908 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CCKAR P32238 1/20 0.35
HTR5A P47898 1/20 0.35
METAP2 P50579 1/20 0.34
MAPT P10636 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
ALDH1A1 P00352 2/20 0.34
ALPG P10696 1/20 0.34
HPGD P15428 1/20 0.34
BUB1 O43683 1/20 0.34
GRK6 P43250 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
APP P05067 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3633027 0.92 PRMT6 (0.39) PRMT6HDAC1HDAC2MAPTHTR1D
SCHEMBL3637444 0.83 PRMT6 (0.41) PRMT6HDAC1HDAC2HTR1AMETAP2
SCHEMBL3637348 0.81 HTT (0.47) PRMT6MAPTALDH1A1HPGDLMNA
SCHEMBL3638993 0.81 HAO1 (0.41) METAP2MAPTNPSR1TDP1ALDH1A1
SCHEMBL3640679 0.80 MAOB (0.40) MAPTNPSR1TDP1ALDH1A1ALPG
SCHEMBL3635913 0.79 MAPT (0.49) MAPTNPSR1TDP1ALDH1A1ALPG
SCHEMBL3641235 0.79 MAOB (0.43) MAPTNPSR1TDP1ALDH1A1ALPG
SCHEMBL3633809 0.79 METAP2 (0.40) HTR1AMETAP2MAPTNPSR1TDP1
SCHEMBL3635936 0.79 PRMT6 (0.41) PRMT6METAP2MAPTNPSR1TDP1
SCHEMBL3638998 0.78 HAO1 (0.40) METAP2MAPTNPSR1TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 PRMT6 2027/4885HDAC1 658/4885HDAC2 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.